CClinicalTrials.gg
Status unknownNCT00386737Updated Oct 12, 2006

Development of a Breath Analyzer for Asthma Screening

An observational study in Asthma, sponsored by Ekips Technologies. Status unknown at 1 site in United States. Open to participants aged 4 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2006-10-12.

Sponsored by Ekips Technologies · Observational

The sponsor has not verified this record recently (last verified Oct 2006), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Defined population
Time perspective
Other
Enrollment
2,000
Ages
4 Years to 65 Years
Sex
All
01

Study summary

Annually, asthma is responsible for 1 million emergency room visits, 400,000 hospitalizations, and 5000 deaths according to the NHLBI. In addition, 10 million missed school-days per year and 100 million days of restricted activity are attributed to this disease. While there is no known cause or cure for asthma, recent studies have shown that hospitalizations and emergency room visits can be reduced by as much as 78% and 73%, respectively, when the disease is properly managed. According to the EPA, the occurance of children with asthma more than doubled the rate of two decades ago; in 2001 the percentage of asthmatic children was 8.7% (6.3 million children).

Properly managing asthma is nontrivial and can often require an asthma specialist. The difficulty in diagnosing and managing asthma lies primarily in the lack of available clinical technologies capable of assessing airway inflammation, an early and persistent component of asthma. Accordingly, the National Institutes of Health (NIH) guidelines for the diagnosis and management of asthma strongly recommend long term anti-inflammatory therapies, such as oral or inhaled corticosteroids, to reverse airway inflammation in an effort to prevent irreversible airway damage, termed "airway remodeling". The medical community has expressed the need for more objective and noninvasive measures of airway inflammation for diagnosing asthma and monitoring the effectiveness and compliance of anti-inflammatory therapies.

The clinical research plan is designed to evaluate airway inflammation associated with asthma. In this human subjects study, a non-invasive exhaled breath analysis sensor, called the Breathmeter, will be used to measure eNO concentrations in children and adults (ages 4-65) with a broad range of respiratory disorders as well as those with no known respiratory disorders. Breath donations will be simple and straightforward presenting little to no discomfort to volunteers.

Read the detailed description

The study plan is divided into two sections: in-clinic studies and large-scale outreach screening.

(A). Clinical Studies The clinical study is intended to obtain data characterizing eNO concentrations within individual groups of subjects listed in the inclusion criteria. The type of this study is "non-invasive", and the study design is "diagnosis/ treatment monitoring, and efficacy". The study will seek to recruit subjects who fall into one of the categories listed in the inclusion criteria below. The number of subjects (n) to be recruited for each category is given and is estimated based on the past number of subjects mainly at the Ekips Technologies, The Oklahoma Allergy \& Asthma Clinic, and the Norman Lung Center sites.

Inclusion Criteria (Total Number of Subjects, n = 700)

Both genders are eligible for this study:

  1. Healthy subjects (n=120)
  2. Asthma (Total n=450) [diagnosed according to NHLBI/ NAEPP Guidelines (1998)]

    1. Non-treated or B2-agonist treated asthmatics (n=150),
    2. Glucocorticoid treated asthmatics, (n=150),
    3. Leukotriene Antagonist treated asthmatics, (n=75),
    4. Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75).
  3. Acute respiratory illnesses (n=65

    a) Sinusitis (Acute and Chronic), b) Influenza, c) Common cold, d)Pneumonia, e)Related symptoms, but no diagnosis.

  4. Allergies (n=65) a) Atopic dermatitis, b) Allergic rhinitis, c) Seasonal allergies.

Healthy Subjects Recruiting

Healthy subjects will be recruited from visitors and patients at the study sites. Visitors may include relatives or friends accompanying patients. Healthy employees at the study sites may be asked to participate in the study. Patients, visitors, and employees will be told that do not have to participate if they do not want to.

Exclusion Criteria

Subjects younger than 4 and older than 65 will be excluded from the study. Pregnant women will also be excluded from the study.

Duration of Participation

For each visit, the participant in the study will be asked to donate up to 3 breath samples for the first visit. The total time required for breath donations and measurements will be about 5 minutes. An additional five minutes of a subject's time are needed to complete a short interview if the information needed is not already available.

Asthmatic or suspected asthmatic patients, both treated and non-treated will be asked to donate breath during additional visits if convenient. Follow-up measurements may be performed during regularly scheduled office visits.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Breath Testing
  • Laser Spectroscopy
  • eNO
  • Nitric Oxide
  • Lower Airway Inflammation
  • Carbon Dioxide
  • CO2
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 2,000 is above the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

This is the only study on the registry with Ekips Technologies as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy subjects (n=120)
  • Asthma (Total n=450) [diagnosed according to NHLBI/ NAEPP Guidelines (1998)]

    • Non-treated or B2-agonist treated asthmatics (n=150),
    • Glucocorticoid treated asthmatics, (n=150),
    • Leukotriene Antagonist treated asthmatics, (n=75),
    • Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75).
  • Acute respiratory illnesses (n=65

    • Sinusitis (Acute and Chronic),
    • Influenza,
    • Common cold,
    • Pneumonia,
    • Related symptoms, but no diagnosis.
  • Allergies (n=65)

    • Atopic dermatitis,
    • Allergic rhinitis,
    • Seasonal allergies.

Exclusion criteria

Exclusion Criteria:

  • Younger than 4
  • Older than 65
  • Pregnant
05

Study design

Observational model
Defined population
Time perspective
Other
Enrollment
2,000 participants
06

Study locations

1 of 1 sites recruiting
  • Ekips Technologies, Inc.
    Norman, Oklahoma 73069, United States
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00386737
Lead sponsor
Ekips Technologies
Collaborators
American Lung Association
First posted
Oct 12, 2006
Start date
Sep 2004
Completion
Feb 2007
Last update
Oct 12, 2006

Study contacts

Tanya Reich, BS
Contact
treich@ekipstech.com
(405) 307-8803 ext. 114
G. Carl Gibson, BBA
Contact
cgibson@ekipstech.com
(405) 307-8803 ext. 110
Khosrow Namjou, Ph.D.
principal investigator · Ekips Technologies, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion